Nothing Special   »   [go: up one dir, main page]

HRP20230306T1 - Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori - Google Patents

Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori Download PDF

Info

Publication number
HRP20230306T1
HRP20230306T1 HRP20230306TT HRP20230306T HRP20230306T1 HR P20230306 T1 HRP20230306 T1 HR P20230306T1 HR P20230306T T HRP20230306T T HR P20230306TT HR P20230306 T HRP20230306 T HR P20230306T HR P20230306 T1 HRP20230306 T1 HR P20230306T1
Authority
HR
Croatia
Prior art keywords
methyl
tetrahydro
imidazo
cancer
membered
Prior art date
Application number
HRP20230306TT
Other languages
English (en)
Inventor
Liangxing Wu
Kaijiong Xiao
Wenqing Yao
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66625434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20230306(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Corporation filed Critical Incyte Corporation
Publication of HRP20230306T1 publication Critical patent/HRP20230306T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (21)

1. Spoj, naznačen time, da je predstavljen Formulom I: [image] ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, pri čemu: R1 je metil, CN, F, Cl, ili Br; R2 je metil, CN, F, Cl, ili Br; i R3 je H, C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril, 5-člani do 6-člani heteroaril-C1-2 alkil, 4-člani do 6-člani heterocikloalkil ili 4-člani do 6-člani heterocikloalkil-C1-2 alkil-, gdje svaki 5-člani do 6-člani heteroaril, 5-člani do 6-člani heteroaril-C1-2 alkil, 4-člani do 6-člani heterocikloalkil i 4-člani do 6-člani heterocikloalkil-C1-2 alkil-, ima jedan ili dva heteroatoma kao članove u prstenu, odabrane od O, N i S, i pri čemu je svaki C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril, 5-člani do 6-člani heteroaril-C1-2 alkil, 4-člani do 6-člani heterocikloalkil i 4-člani do 6-člani heterocikloalkil-C1-2 alkil- od R3, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2, COOH, OH, CON(CH3)2, CH3, F, Cl, Br, CN, etila, i propila.
2. Spoj prema patentnom zahtjevu 1, naznačen time, da ima Formulu I: [image] ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, pri čemu: R1 je metil, CN, F, Cl, ili Br; R2 je metil, CN, F, Cl, ili Br; i R3 je H, C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril, 5-člani do 6-člani heteroaril-C1-2 alkil, 4-člani do 6-člani heterocikloalkil ili 4-člani do 6-člani heterocikloalkil-C1-2 alkil-, gdje svaki 5-člani do 6-člani heteroaril, 5-člani do 6-člani heteroaril-C1-2 alkil, 4-člani do 6-člani heterocikloalkil i 4-člani do 6-člani heterocikloalkil-C1-2 alkil-, ima jedan ili dva heteroatoma kao članove u prstenu, odabrane od O, N i S, i pri čemu je svaki C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril, 5-člani do 6-člani heteroaril-C1-2 alkil, 4-člani do 6-člani heterocikloalkil i 4-člani do 6-člani heterocikloalkil-C1-2 alkil- od R3, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2, COOH, i OH.
3. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, naznačen time, da: (a) R1 je metil, F, Cl, ili Br; ili (b) R1 je metil; ili (c) R1 je F, Cl, ili Br; ili (d) R1 je Cl.
4. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, naznačen time, da: (a) R2 je metil; ili (b) R2 je CN; ili (c) R2 je F, Cl, ili Br; ili (d) R2 je Cl.
5. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, naznačen time, da: (a) R1 je Cl i R2 je Cl; ili (b) R1 je Cl i R2 je metil; ili (c) R1 je metil i R2 je Cl; ili (d) R1 je Cl i R2 je CN; ili (e) R1 je metil i R2 je metil.
6. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, naznačen time, da: (a) R3 je H, C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, ili 4-člani do 6-člani heterocikloalkil, gdje svaki 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil, ima jedan ili dva heteroatoma kao članove u prstenu, odabrane od O, N i S, i pri čemu je svaki C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil od R3, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2, COOH, OH, CON(CH3)2, i CH3; ili (b) R3 je C1-4 alkil, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od COOH, OH, i CON(CH3)2; ili (c) R3 je C3-8 cikloalkil, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od COOH, OH, i CH3; ili (d) R3 je ciklobutil, 4-hidroksicikloheksil, (1-karboksiciklopropil)metil, (4-karboksibiciklo[2.2.1]heptan-1-il)etil, (4-karboksibiciklo[2.2.1]heptan-1-il)metil, (4-karboksibiciklo[2.2.2]oktan-1-il)metil, (3-karboksibiciklo[1.1.1]pentan-1-il)metil, 4-karboksifenetil, (4-karboksicikloheksil)etil, ili 4-karboksi-4-metilcikloheksil; ili (e) R3 je H, metil, etil, izopropil, 1,3-dihidroksipropan-2-il, 2,3-dihidroksipropil, 2-hidroksipropil, 2-hidroksietil, 3-hidroksipropil, karboksimetil, 3-karboksipropil, 2-karboksi-2-metilpropil, ciklobutil, 4-hidroksicikloheksil, (1-karboksiciklopropil)metil, (4-karboksibiciklo[2.2.1]heptan-1-il)etil, (4-karboksibiciklo[2.2.1]heptan-1-il)metil, (4-karboksibiciklo[2.2.2]oktan-1-il)metil, (3-karboksibiciklo[1.1.1]pentan-1-il)metil, 4-karboksifenetil, (1H-pirazol-3-il)metil, tetrahidro-2H-piran-4-il, 1-karbamoilpiperidin-4-il, 1-sulfamoilpiperidin-4-il, (3-karboksi-1H-pirazol-5-il)metil, 4-karboksibutil, (4-karboksicikloheksil)etil, ili 4-karboksi-4-metilcikloheksil.
7. Spoj prema bilo kojem od patentnih zahtjeva 1-5, ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, naznačen time, da: (a) R3 je H, C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, ili 4-člani do 6-člani heterocikloalkil, gdje svaki 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil, ima jedan ili dva heteroatoma kao članove u prstenu, odabrane od O, N i S, i pri čemu je svaki C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil od R3, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2, COOH, i OH; ili (b) R3je H; ili (c) R3 je C1-4 alkil, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od COOH i OH; ili (d) R3 je metil, etil, izopropil, 1,3-dihidroksipropan-2-il, 2,3-dihidroksipropil, 2-hidroksipropil, 2-hidroksietil, 3-hidroksipropil, karboksimetil, 3-karboksipropil, 2-karboksi-2-metilpropil, ili 4-karboksibutil; ili (e) R3 je metil, etil, izopropil, 1,3-dihidroksipropan-2-il, 2,3-dihidroksipropil, 2-hidroksipropil, 2-hidroksietil, 3-hidroksipropil, karboksimetil, 3-karboksipropil, ili 2-karboksi-2-metilpropil; ili (f) R3 je C3-8cikloalkil, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od COOH i OH; ili (g) R3 je C3-8 cikloalkil-C1-2 alkil-, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od COOH i OH; ili (h) R3 je C6-10 aril-C1-2 alkil, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od COOH i OH; ili (i) R3 je ciklobutil, 4-hidroksicikloheksil, (1-karboksiciklopropil)metil, (4-karboksibiciklo[2.2.1]heptan-1-il)etil, (4-karboksibiciklo[2.2.1]heptan-1-il)metil, (4-karboksibiciklo[2.2.2]oktan-1-il)metil, (3-karboksibiciklo[1.1.1]pentan-1-il)metil, ili 4-karboksifenetil; ili (j) R3 je 5-člani do 6-člani heteroaril-C1-2 alkil, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2 i COOH; ili (k) R3 je 4-člani do 6-člani heterocikloalkil, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2 i COOH; ili (l) R3 je (1H-pirazol-3-il)metil, tetrahidro-2H-piran-4-il, 1-karbamoilpiperidin-4-il, 1-sulfamoilpiperidin-4-il, ili (3-karboksi-1H-pirazol-5-il)metil; ili (m) R3 je H, metil, etil, izopropil, 1,3-dihidroksipropan-2-il, 2,3-dihidroksipropil, 2-hidroksipropil, 2-hidroksietil, 3-hidroksipropil, karboksimetil, 3-karboksipropil, 2-karboksi-2-metilpropil, ciklobutil, 4-hidroksicikloheksil, (1-karboksiciklopropil)metil, (4-karboksibiciklo[2.2.1]heptan-1-il)etil, (4-karboksibiciklo[2.2.1]heptan-1-il)metil, (4-karboksibiciklo[2.2.2]oktan-1-il)metil, (3-karboksibiciklo[1.1.1]pentan-1-il)metil, 4-karboksifenetil, (1H-pirazol-3-il)metil, tetrahidro-2H-piran-4-il, 1-karbamoilpiperidin-4-il, 1-sulfamoilpiperidin-4-il, ili (3-karboksi-1H-pirazol-5-il)metil.
8. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, naznačen time, da: (a) R1 je metil, CN, F, Cl, ili Br; R2 je metil, CN, F, Cl, ili Br; i R3 je H, C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, ili 4-člani do 6-člani heterocikloalkil, gdje svaki 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil, ima jedan ili dva heteroatoma kao članove u prstenu, odabrane od O, N i S, i pri čemu je svaki C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil od R3, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2, COOH, OH, CON(CH3)2, i CH3; ili (b) R1 je metil, CN, F, Cl, ili Br; R2 je metil, CN, F, Cl, ili Br; i R3 je H, C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, ili 4-člani do 6-člani heterocikloalkil, gdje svaki 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil, ima jedan ili dva heteroatoma kao članove u prstenu, odabrane od O, N i S, i pri čemu je svaki C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil od R3, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2, COOH, i OH; ili (c) R1 je metil, ili Cl; R2 je metil, CN, ili Cl; i R3 je H, C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, ili 4-člani do 6-člani heterocikloalkil, gdje svaki 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil, ima jedan ili dva heteroatoma kao članove u prstenu, odabrane od O, N i S, i pri čemu je svaki C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil od R3, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2, COOH, OH, CON(CH3)2, i CH3; ili (d) R1 je metil, ili Cl; R2 je metil, CN, ili Cl; i R3 je H, C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, ili 4-člani do 6-člani heterocikloalkil, gdje svaki 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil, ima jedan ili dva heteroatoma kao članove u prstenu, odabrane od O, N i S, i pri čemu je svaki C1-4 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-2 alkil-, C6-10 aril-C1-2 alkil, 5-člani do 6-člani heteroaril-C1-2 alkil, i 4-člani do 6-člani heterocikloalkil od R3, opcionalno supstituiran s jednim ili dva supstituenta neovisno odabrana od CONH2, SO2NH2, COOH, i OH; ili (e) R1 je metil, ili Cl; R2 je metil, CN, ili Cl; i R3 je H, metil, etil, izopropil, 1,3-dihidroksipropan-2-il, 2,3-dihidroksipropil, 2-hidroksipropil, 2-hidroksietil, 3-hidroksipropil, karboksimetil, 3-karboksipropil, 2-karboksi-2-metilpropil, ciklobutil, 4-hidroksicikloheksil, (1-karboksiciklopropil)metil, (4-karboksibiciklo[2.2.1]heptan-1-il)etil, (4-karboksibiciklo[2.2.1]heptan-1-il)metil, (4-karboksibiciklo[2.2.2]oktan-1-il)metil, (3-karboksibiciklo[1.1.1]pentan-1-il)metil, 4-karboksifenetil, (1H-pirazol-3-il)metil, tetrahidro-2H-piran-4-il, 1-karbamoilpiperidin-4-il, 1-sulfamoilpiperidin-4-il, (3-karboksi-1H-pirazol-5-il)metil, 4-karboksibutil, (4-karboksicikloheksil)etil, ili 4-karboksi-4-metilcikloheksil; ili (f) R1 je metil, ili Cl; R2 je metil, CN, ili Cl; i R3 je H, metil, etil, izopropil, 1,3-dihidroksipropan-2-il, 2,3-dihidroksipropil, 2-hidroksipropil, 2-hidroksietil, 3-hidroksipropil, karboksimetil, 3-karboksipropil, 2-karboksi-2-metilpropil, ciklobutil, 4-hidroksicikloheksil, (1-karboksiciklopropil)metil, (4-karboksibiciklo[2.2.1]heptan-1-il)etil, (4-karboksibiciklo[2.2.1]heptan-1-il)metil, (4-karboksibiciklo[2.2.2]oktan-1-il)metil, (3-karboksibiciklo[1.1.1]pentan-1-il)metil, 4-karboksifenetil, (1H-pirazol-3-il)metil, tetrahidro-2H-piran-4-il, 1-karbamoilpiperidin-4-il, 1-sulfamoilpiperidin-4-il, ili (3-karboksi-1H-pirazol-5-il)metil.
9. Spoj prema patentnom zahtjevu 1, naznačen time, da se spoj bira od sljedećih: (a) 4-(2-(2-((2,2'-dikloro-3'-(1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(1-metil-5-(tetrahidro-2H-piran-4-il)-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(1,5-dimetil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(5-etil-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(5-izopropil-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(5-ciklobutil-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(1-karbamoilpiperidin-4-il)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(1-metil-5-(1-sulfamoilpiperidin-4-il)-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-((1H-pirazol-3-il)metil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(5-(1,3-dihidroksipropan-2-il)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (R)-4-(2-(2-((2,2'-dikloro-3'-(5-(2,3-dihidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (S)-4-(2-(2-((2,2'-dikloro-3'-(5-(2,3-dihidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (R)-4-(2-(2-((2,2'-dikloro-3'-(5-(2-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (S)-4-(2-(2-((2,2'-dikloro-3'-(5-(2-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(5-(2-hidroksietil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(5-(3-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4,4'-(((((2,2'-dikloro-[1,1'-bifenil]-3,3'-diil)bis(azandiil))bis(karbonil))bis(1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-2,5-diil))bis(etan-2,1-diil))bis(biciklo[2.2.1]heptan-1-karboksilna kiselina); 4-((2-((3'-(5-(2-(4-karboksibiciklo[2.2.1]heptan-1-il)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)metil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(karboksimetil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(3-karboksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(karboksi-2-metilpropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-((1-karboksiciklopropil)metil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-((2-((3'-(5-(2-(4-karboksibiciklo[2.2.1]heptan-1-il)etil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)metil)biciklo[2.2.2]oktan-1-karboksilna kiselina; 3-((2-((3'-(5-(2-(4-karboksibiciklo[2.2.1]heptan-1-il)etil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)metil)biciklo[1.1.1]pentan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(4-karboksifenetil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 5-((2-((3'-(5-(2-(4-karboksibiciklo[2.2.1]heptan-1-il)etil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)metil)biciklo-1H-pirazol-3-karboksilna kiselina; 4-(2-(2-((2-kloro-2'-metil-3'-(1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2-kloro-2'-metil-3'-(1-metil-5-(tetrahidro-2H-piran-4-il)-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2-kloro-2'-metil-3'-(1,5-dimetil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2'-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(1-karbamoilpiperidin-4-il)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2-kloro-2'-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (R)-4-(2-(2-((2-kloro-3'-(5-(2-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2'-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (S)-4-(2-(2-((2-kloro-3'-(5-(2-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2'-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2-kloro-3'-(5-(2-hidroksietil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2'-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4,4'-(((((2-kloro-2'-metil-[1,1'-bifenil]-3,3'-diil)bis(azandiil))bis(karbonil))bis(1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-2,5-diil))bis(etan-2,1-diil))bis(biciklo[2.2.1]heptan-1-karboksilna kiselina); 4-((2-((3'-(5-(2-(4-karboksibiciklo[2.2.1]heptan-1-il)etil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2'-kloro-2-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)metil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(4-karboksifenetil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2-kloro-2'-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2'-kloro-2-metil-3'-(1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2'-kloro-2-metil-3'-(1-metil-5-(tetrahidro-2H-piran-4-il)-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2'-kloro-3'-(1,5-dimetil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(1-karbamoilpiperidin-4-il)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2'-kloro-2-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (R)-4-(2-(2-((2'-kloro-3'-(5-(2-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (S)-4-(2-(2-((2'-kloro-3'-(5-(2-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2'-kloro-3'-(5-(2-hidroksietil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-((2-((3'-(5-(2-(4-karboksibiciklo[2.2.1]heptan-1-il)etil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2-kloro-2'-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)metil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(4-karboksifenetil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2'-kloro-2-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2-kloro-2'-cijano-3'-(1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2-kloro-2'-cijano-3'-(1-metil-5-(tetrahidro-2H-piran-4-il)-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2-kloro-2'-cijano-3'-(1,5-dimetil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (R)-4-(2-(2-((2-kloro-2'-cijano-3'-(5-(2-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2-kloro-2'-cijano-3'-(5-(2-hidroksietil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4,4'-(((((2-kloro-2'-cijano-[1,1'-bifenil]-3,3'-diil)bis(azandiil))bis(karbonil))bis(1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-2,5-diil))bis(etan-2,1-diil))bis(biciklo[2.2.1]heptan-1-karboksilna kiselina); 4-((2-((3'-(5-(2-(4-karboksibiciklo[2.2.1]heptan-1-il)etil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2'-kloro-2-cijano-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)metil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dimetil-3'-(1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4,4'-(((((2,2'-dimetil-[1,1'-bifenil]-3,3'-diil)bis(azandiil))bis(karbonil))bis(1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-2,5-diil))bis(etan-2,1-diil))bis(biciklo[2.2.1]heptan-1-karboksilna kiselina); 4-((2-((3'-(5-(2-(4-karboksibiciklo[2.2.1]heptan-1-il)etil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dimetil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)metil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dimetil-3'-(1-metil-5-(tetrahidro-2H-piran-4-il)-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (R)-4-(2-(2-((3'-(5-(2-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dimetil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; (S)-4-(2-(2-((3'-(5-(2-hidroksipropil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dimetil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(2-hidroksietil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dimetil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(5-(4-hidroksicikloheksil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; i 4-(2-(2-((2-kloro-3'-(5-(4-hidroksicikloheksil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2'-metil-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; ili njihova farmaceutski prihvatljiva sol; ili (b) 4-(2-(2-((3'-(5-(2-(trans-4-karboksicikloheksil)etil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(4-karboksibutil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((2,2'-dikloro-3'-(5-(5-(dimetilamino)-5-oksopentil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; 4-(2-(2-((3'-(5-(cis-4-karboksi-4-metilcikloheksil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; i 4-(2-(2-((3'-(5-(trans-4-karboksi-4-metilcikloheksil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)etil)biciklo[2.2.1]heptan-1-karboksilna kiselina; ili njihova farmaceutski prihvatljiva sol.
10. Spoj prema patentnom zahtjevu 1, naznačen time, da je 4,4'-(((((2-kloro-2'-metil-[1,1'-bifenil]-3,3'-diil)bis(azandiil))bis(karbonil))bis(1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-2,5-diil))bis(etan-2,1-diil))bis(biciklo[2.2.1]heptan-1-karboksilna kiselina), ili njezina farmaceutski prihvatljiva sol.
11. Spoj prema patentnom zahtjevu 1, naznačen time, da je 4,4'-(((((2,2'-dikloro-[1,1'-bifenil]-3,3'-diil)bis(azandiil))bis(karbonil))bis(1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-2,5-diil))bis(etan-2,1-diil))bis(biciklo[2.2.1]heptan-1-karboksilna kiselina), ili njezina farmaceutski prihvatljiva sol.
12. Spoj prema patentnom zahtjevu 1, naznačen time, da je 4-((2-((3'-(5-(2-(4-karboksibiciklo[2.2.1]heptan-1-il)etil)-1-metil-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-2-karboksamido)-2,2'-dikloro-[1,1'-bifenil]-3-il)karbamoil)-1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-5-il)metil)biciklo[2.2.1]heptan-1-karboksilna kiselina, ili njezina farmaceutski prihvatljiva sol.
13. Spoj prema patentnom zahtjevu 1, naznačen time, da je 4,4'-(((((2-kloro-2'-cijano-[1,1'-bifenil]-3,3'-diil)bis(azandiil))bis(karbonil))bis(1-metil-1,4,6,7-tetrahidro-5H-imidazo[4,5-c]piridin-2,5-diil))bis(etan-2,1-diil))bis(biciklo[2.2.1]heptan-1-karboksilna kiselina), ili njezina farmaceutski prihvatljiva sol.
14. Farmaceutski pripravak, naznačen time, da sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 8, ili njegovu farmaceutski prihvatljivu sol ili njegov stereoizomer, ili spoj prema bilo kojem od patentnih zahtjeva 9 do 13, ili njegovu farmaceutski prihvatljivu sol, te farmaceutski prihvatljivo pomoćno sredstvo ili nosač.
15. Spoj prema bilo kojem od patentnih zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, ili spoj prema bilo kojem od patentnih zahtjeva 9 do 13, ili njegova farmaceutski prihvatljiva sol, naznačen time, da je za uporabu u inhibiranju interakcije PD-1/PD-L1.
16. Spoj prema bilo kojem od patentnih zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, ili spoj prema bilo kojem od patentnih zahtjeva 9 do 13, ili njegova farmaceutski prihvatljiva sol, naznačen time, da je za uporabu u liječenju bolesti ili poremećaja koji su povezani s inhibiranjem interakcije PD-1/PD-L1.
17. Spoj, sol, ili stereoizomer za uporabu prema patentnom zahtjevu 16, naznačen time, da se kod bolesti ili poremećaja radi o zaraznoj bolesti, upali, autoimunoj bolesti, raku, ili neurodegenerativnom poremećaju.
18. Spoj, sol, ili stereoizomer za uporabu prema patentnom zahtjevu 16, naznačen time, da se kod bolesti ili poremećaja radi o raku.
19. Spoj, sol ili stereoizomer za uporabu prema patentnom zahtjevu 18, naznačen time, da: (a) rak se bira od sljedećih: rak kostiju, rak gušterače, rak kože, rak glave i vrata, kožni maligni melanom, očni maligni melanom, rak maternice, rak jajnika, rak rektuma, rak analne regije, rak abdomena, rak testisa, karcinom falopijevih cijevi, rak endometrija, karcinom cerviksa, karcinom vagine, karcinom vulve, ne-Hodgkinov limfom, rak jednjaka, rak malog crijeva, rak endokrinog sustava, rak tiroidne žlijezde, rak paratiroidne žlijezde, rak adrenalne žlijezde, sarkom mekog tkiva, rak uretre, rak penisa, kronične ili akutne leukemije, solidni tumori u djetinjstvu, limfom limfocita, rak mokraćnog mjehura, rak bubrega, karcinom bubrežne zdjelice, neoplazma središnjeg živčanog sustava (CNS), primarni limfom središnjeg živčanog sustava (CNS), tumorska angiogeneza, tumor kralježnice, gliom moždanog debla, pituitarni adenom, Kaposijev sarkom, epidermoidni rak, rak rožnatih stanica, limfom T stanica, vrste raka koje su inducirane okolišem uključujući one koje su inducirane azbestom, melanom, metastatski maligni melanom, rak bubrega, karcinom svijetlih bubrežnih stanica, rak prostate, adenokarcinom prostate koji je hormonski otporan, rak dojke, rak debelog crijeva, rak pluća, rak rožnatih stanica glave i vrata, urotelni rak, vrste raka s velikom mikrosatelitskom nestabilnošću (MSIhigh), solidni tumori, solidni tumori raka prostate, solidni tumori raka debelog crijeva, solidni tumori raka jednjaka, solidni tumori raka endometrija, solidni tumori raka bubrega, solidni tumori raka jetre, solidni tumori raka gušterače, solidni tunori raka želuca, solidni tumori raka dojke, solidni tumori raka pluća, solidni tumori raka glave i vrata, solidni tumori tiroidnog raka, solidni tumori glioblastoma, solidni tumori sarkoma, solidni tumori raka mokraćnog mjehura, povratni ne-Hodgkinov limfom, uporni ne-Hodgkinov limfom, periodični folikularni ne-Hodgkinov limfom, Hodgkinov limfom, holangiokarcinom, rak žučnih vodova, rabdomiosarkom, leiomiosarkom, hepatocelularni karcinom, Ewingov sarkom, rak mozga, tumor mozga, astrocitom, neuroblastom, karcinom bazalnih stanica, hondrosarkom, epitelni sarkom, rak oka, gastrointestinalni rak, gastrointestinalni stromalni tumori, leukemija kosmatih stanica, intestinalni rak, rak otočićkih stanica, oralni rak, rak usta, rak grla, rak grkljana, rak usne, mezoteliom, rak vrata, rak nosne šupljine, okularni rak, okularni melanom, rak karlice, karcinom renalnih stanica, rak žlijezde slinovnice, rak sinusa, rak kičme, rak jezika, tubularni karcinom, rak mokraćnih kanala, vrste raka genitourinarnog trakta, vrste raka živčanog sustava, hematološke vrste raka, hematološki limfomi, hematološke leukemije, akutna limfoblastična leukemija (ALL), akutna mijeloična leukemija (AML), akutna promijelocitna leukemija (APL), kronična limfocitna leukemija (CLL), kronična mijeloična leukemija (CML), difuzni limfom velikih B stanica (DLBCL), limfom plaštenih stanica, mijeloproliferativne bolesti, primarna mijelofibroza (PMF), policitemija vera (PV), esencijalna trombocitoza (ET), sindrom mijelodisplazije (MDS), akutni limfoblastični limfom T stanica (T-ALL), multipli mijelom (MM), sarkomi, osteosarkomi, angiosarkomi, fibrosarkomi, liposarkomi, miksomi, rabdomiom, rabdosarkom, fibrom, lipom, harmatom, teratom, rak ne-malih stanica pluća (NSCLC), rak malih stanica pluća, bronhogeni karcinom, bronhogeni sarkom rožnatih stanica, bronhogeni karcinom nediferenciranih malih stanica, bronhogeni karcinom nediferenciranih velikih stanica, bronhogeni adenokarcinom, alveolni (bronhijalni) karcinom, bronhijalni adenom, hondromatozni hamartom, karcinom rožnatih stanica jednjaka, adenokarcinom jednjaka, leiomiosarkom jednjaka, limfom jednjaka, karcinom abdomena, limfom abdomena, leiomiosarkom abdomena, duktalni adenokarcinom, inzulinom, glukagonom, gastrinom, karcinoidni tumori gušterače, vipom, vrste raka malog crijeva, adenokarcinom malog crijeva, limfom malog crijeva, karcionidni tumori malog crijeva, leiomiom malog crijeva, hemangiom malog crijeva, lipom malog crijeva, neurofibrom malog crijeva, fibrom malog crijeva, vrste raka velikog crijeva, adenokarcinom velikog crijeva, tubularni adenom velikog crijeva, vilozni adenom velikog crijeva, hamartom velikog crijeva, leiomiom velikog crijeva, kolorektalni rak, adenokarcinom bubrega, Wilmov tumor (nefroblastom), karcinom rožnatih stanica mokraćnog mjehura, karcinom prijelaznih stanica mokraćnog mjehura, adenokarcinom mokraćnog mjehura, karcinom rožnatih stanica uretre, karcinom prijelaznih stanica uretre, adenokarcinom uretre, adenokarcinom prostate, sarkom prostate, vrste raka testisa, seminom testisa, teratom testisa, embrionalni karcinom testisa, teratokarcinom testisa, horiokarcinom testisa, sarkom testisa, karcinom intersticijskih stanica testisa, fibrom testisa, fibroadenom testisa, adenomatoidni tumori testisa, lipom testisa, vrste raka jetre, hepatom, hepatoblastom, hepatocelularni adenom, hemangiom, maligni fibrozni histiocitom, maligni limfom (sarkom retikularnih stanica), maligni tumorski hordom divovskih stanica, osteohronfrom (osteokartilagne ekstoze), benigni hondrom, hondroblastom, hondromiksofibrom, osteoidni osteom, tumori divovskih stanica, vrste raka lubanje, osteom, granulom, ksantom, osteitis deformans, meningne vrste raka, meningiom, meningiosarkom, gliomatoza, moždani astrocitom, moždani meduloblastom, moždani gliom, moždani ependimom, moždani germinom (pinealom), moždani glioblastom, multiformni moždani glioblastom, moždani oligodendrogliom, švanom mozga, moždani retinoblastom, kongenitalni tumori mozga, vrste raka kralježnice, neurofibrom kralježnice, meningiom kralježnice, gliom kralježnice, sarkom kralježnice, bolest Lhermitte-Duclos, ginekološke vrste raka, vrste raka maternice, endometrijski karcinom, predtumorna cervikalna displazija, karcinom jajnika, serozni cistadenokarcinom, mucinozni cistadenokarcinom, neklasificirani karcinom, tumori granulozno-tekalnih stanica, tumori Sertoli-Leydig stanica, disgerminom, maligni teratom, karcinom rožnatih stanica vulve, karcinom intraepitelija vulve, adenokarcinom vulve, fibrosarkom vulve, melanom vulve, karcinom svijetlih stanica vagine, karcinom rožnatih stanica vagine, botrioidni sarkom, embrionalni rabdomiosarkom, karcinom rožnatih stanica, atipičan madež displastični nevus, lipom kože, angiom, dermatofibrom, keloidi, trostruko negativni rak dojke (TNBC), i urotelni karcinom; ili (b) rak je metastatski rak koji eksprimira PD-L1; ili (c) rak je rak pluća; ili (d) rak je rak malih stanica pluća; ili (e) rak je rak ne-malih stanica pluća (NSCLC); ili (f) rak je karcinom rožnatih stanica; ili (g) rak je hepatski rak; ili (h) rak je hepatocelularni karcinom; ili (i) rak je melanom; ili (j) rak je rak mokraćnog mjehura; ili (k) rak je rak uretre; ili (l) rak je renalni rak; ili (m) rak je karcinom svijetlih bubrežnih stanica.
20. Spoj, sol ili stereoizomer za uporabu prema patentnom zahtjevu 18, naznačen time, da: (a) rak se bira od sljedećih: kožni melanom, invazivni karcinom dojke, karcinom rožnatih stanica glave i vrata, nemišićni invazivni rak mokraćnog mjehura (NMIBC), rak žučnog trakta, rak rožnatih stanica ne-malih stanica pluća (NSCLC), karcinom jednjaka, adenokarcinom abdomena, kolorektalni adenokarcinom, urološke vrste raka, papilarni karcinom bubrega, rak zametnih stanica testisa, karcinom hromofobnih bubrežnih stanica, serozni adenokarcinom, i karcinom kožnih rožnatih stanica; ili (b) rak je karcinom kožnih rožnatih stanica.
21. Spoj prema bilo kojem od patentnih zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer, ili spoj prema bilo kojem od patentnih zahtjeva 9 do 13, ili njegova farmaceutski prihvatljiva sol, naznačen time, da je za uporabu u poboljšavanju, pospješivanju i/ili povećavanju imunosnog odgovora kod pacijenta.
HRP20230306TT 2018-05-11 2019-05-10 Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori HRP20230306T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862670249P 2018-05-11 2018-05-11
US201862688164P 2018-06-21 2018-06-21
EP19725627.4A EP3790877B1 (en) 2018-05-11 2019-05-10 Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
PCT/US2019/031728 WO2019217821A1 (en) 2018-05-11 2019-05-10 Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators

Publications (1)

Publication Number Publication Date
HRP20230306T1 true HRP20230306T1 (hr) 2023-05-12

Family

ID=66625434

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20230306TT HRP20230306T1 (hr) 2018-05-11 2019-05-10 Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori

Country Status (31)

Country Link
US (4) US10618916B2 (hr)
EP (2) EP4219492A1 (hr)
JP (2) JP7328995B2 (hr)
KR (1) KR20210018282A (hr)
CN (2) CN118908978A (hr)
AU (2) AU2019267824B2 (hr)
BR (1) BR112020022936A2 (hr)
CA (1) CA3099994A1 (hr)
CL (2) CL2020002922A1 (hr)
CO (1) CO2020015437A2 (hr)
CR (1) CR20200614A (hr)
DK (1) DK3790877T3 (hr)
EC (1) ECSP20079887A (hr)
ES (1) ES2943028T3 (hr)
FI (1) FI3790877T3 (hr)
HR (1) HRP20230306T1 (hr)
HU (1) HUE061503T2 (hr)
JO (1) JOP20200288A1 (hr)
LT (1) LT3790877T (hr)
MD (1) MD3790877T2 (hr)
MX (2) MX2020012045A (hr)
PE (1) PE20211918A1 (hr)
PH (1) PH12020551927A1 (hr)
PL (1) PL3790877T3 (hr)
PT (1) PT3790877T (hr)
RS (1) RS64188B1 (hr)
SA (1) SA520420524B1 (hr)
SG (1) SG11202011165TA (hr)
SI (1) SI3790877T1 (hr)
TW (2) TW202425987A (hr)
WO (1) WO2019217821A1 (hr)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX359293B (es) 2012-06-13 2018-09-24 Incyte Holdings Corp Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr).
SG11201508328PA (en) 2013-04-19 2015-11-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
MX2018006207A (es) 2015-11-19 2018-09-05 Incyte Corp Compuestos heterociclicos como inmunomoduladores.
TWI850624B (zh) 2015-12-22 2024-08-01 美商英塞特公司 作為免疫調節劑之雜環化合物
US20170320875A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3472167T2 (ro) 2016-06-20 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
WO2018005374A1 (en) 2016-06-27 2018-01-04 Chemocentryx, Inc. Immunomodulator compounds
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
MY197501A (en) 2016-12-22 2023-06-19 Incyte Corp Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US11130740B2 (en) 2017-04-25 2021-09-28 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1H-indene analogs and methods using same
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CA3070794A1 (en) 2017-07-28 2019-01-31 Chemocentryx, Inc. Immunomodulator compounds
ES2926540T3 (es) 2017-08-08 2022-10-26 Chemocentryx Inc Inmunomoduladores macrocíclicos
JP7062792B2 (ja) 2018-02-13 2022-05-06 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
MA51232A (fr) 2018-02-22 2020-10-07 Chemocentryx Inc Indane-amines utiles en tant qu'antagonistes de pd-l1
CR20200441A (es) 2018-02-27 2021-03-15 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
US12083118B2 (en) 2018-03-29 2024-09-10 Arbutus Biopharma Corporation Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
WO2019191707A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
FI3790877T3 (fi) 2018-05-11 2023-05-09 Incyte Corp Tetrahydroimidatso[4,5-c]pyridiinijohdannaisia pd-l1-immunomodulaattoreina
CA3100731A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
TWI829716B (zh) 2018-07-05 2024-01-21 美商英塞特公司 作為a2a/a2b 抑制劑之稠合吡嗪衍生物
TWI809427B (zh) 2018-07-13 2023-07-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
MA54947A (fr) 2019-02-15 2021-12-22 Incyte Corp Biomarqueurs de kinase 2 dépendant de la cycline et leurs utilisations
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
CA3139526A1 (en) 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
MA55325A (fr) 2019-06-20 2022-04-27 Chemocentryx Inc Composés pour le traitement de maladies pd-l1
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN114206338A (zh) 2019-07-10 2022-03-18 凯莫森特里克斯股份有限公司 作为pd-l1抑制剂的二氢化茚类
MX2022001671A (es) 2019-08-09 2022-05-13 Incyte Corp Sales de un inhibidor de pd-1/pd-l1.
AR119765A1 (es) 2019-08-14 2022-01-12 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
CA3155852A1 (en) 2019-09-30 2021-04-08 Incyte Corporation PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AS IMMUNOMODULATORS
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
KR20220099970A (ko) 2019-10-11 2022-07-14 인사이트 코포레이션 Cdk2 억제제로서의 이환식 아민
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
AU2020368392A1 (en) 2019-10-16 2022-04-21 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
BR112022006018A2 (pt) 2019-10-16 2022-07-12 Chemocentryx Inc Heteroaril-bifenil amidas para o tratamento de doenças relacionadas à pd-l1
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020385113A1 (en) * 2019-11-11 2022-05-19 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor
CR20220285A (es) 2019-12-04 2022-10-27 Incyte Corp Derivados de un inhibidor de fgfr
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
KR20220125278A (ko) * 2020-01-03 2022-09-14 상하이 한서 바이오메디컬 컴퍼니 리미티드 비페닐 유도체 억제제, 이의 제조 방법 및 용도
US20210205311A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors
JP7387208B2 (ja) * 2020-01-07 2023-11-28 アビスコ セラピューティクス カンパニー リミテッド ビフェニル基フッ素置換二重結合誘導体、その製造方法と薬学的な応用
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202140027A (zh) 2020-03-06 2021-11-01 美商英塞特公司 包含ａｘｌ／ｍｅｒ及ｐｄ—１／ｐｄ／ｌ１抑制劑之組合療法
AU2021254794A1 (en) 2020-04-16 2022-12-15 Incyte Corporation Fused tricyclic KRAS inhibitors
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
US20230234970A1 (en) * 2020-06-17 2023-07-27 Abbisko Therapeutics Co., Ltd. Immunosuppressant, and preparation method therefor and use thereof
WO2022047093A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
MX2023003846A (es) * 2020-10-29 2023-06-23 Shenzhen Chipscreen Biosciences Co Ltd Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo.
MX2023005362A (es) 2020-11-06 2023-06-22 Incyte Corp Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo.
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
CN117500503A (zh) 2020-12-29 2024-02-02 因赛特公司 包含a2a/a2b抑制剂、pd-1/pd-l1抑制剂和抗cd73抗体的组合疗法
CN116710460A (zh) * 2021-01-18 2023-09-05 上海齐鲁制药研究中心有限公司 联苯衍生物及其应用
MX2023009052A (es) 2021-02-01 2023-10-16 Shenzhen Chipscreen Biosciences Co Ltd Compuesto de bifenilo como inmunomodulador, método de preparación para el mismo y uso del mismo.
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
IL309642A (en) 2021-07-07 2024-02-01 Incyte Corp Tricyclic compounds as inhibitors of Kras
EP4370515A1 (en) 2021-07-14 2024-05-22 Incyte Corporation Tricyclic compounds as inhibitors of kras
WO2023034290A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
WO2023049831A1 (en) * 2021-09-24 2023-03-30 Incyte Corporation Treatment of human papillomavirus-associated cancers by pd-l1 inhibitors
JP2024537824A (ja) 2021-10-01 2024-10-16 インサイト・コーポレイション ピラゾロキノリンｋｒａｓ阻害剤
EP4415824A1 (en) 2021-10-14 2024-08-21 Incyte Corporation Quinoline compounds as inhibitors of kras
CN114209815B (zh) * 2021-11-22 2024-04-26 山东大学 一种药物组合物及其制备方法和应用
TW202320792A (zh) 2021-11-22 2023-06-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｋｒａｓ抑制劑之組合療法
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
TW202340215A (zh) 2021-12-22 2023-10-16 美商英塞特公司 Ｆｇｆｒ抑制劑之鹽及固體形式以及其製備方法
TW202346308A (zh) * 2022-04-26 2023-12-01 大陸商深圳微芯生物科技股份有限公司 作為免疫調節劑的聯苯類化合物的鹽型、晶型及其製備方法
WO2023207933A1 (zh) * 2022-04-26 2023-11-02 深圳微芯生物科技股份有限公司 一种作为免疫调节剂的联苯类化合物的晶型及其制备方法
US20230399342A1 (en) 2022-06-08 2023-12-14 Incyte Corporation Tricyclic triazolo compounds as dgk inhibitors
US20240101557A1 (en) 2022-07-11 2024-03-28 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
WO2024108100A1 (en) 2022-11-18 2024-05-23 Incyte Corporation Heteroaryl fluoroalkenes as dgk inhibitors
WO2024151346A1 (en) 2023-01-12 2024-07-18 Incyte Corporation Heteroaryl fluoroalkenes as dgk inhibitors
WO2024196989A1 (en) * 2023-03-20 2024-09-26 University Of Central Florida Research Foundation, Inc. Anti-malarial therapy
WO2024220532A1 (en) 2023-04-18 2024-10-24 Incyte Corporation Pyrrolidine kras inhibitors
US20240368156A1 (en) 2023-04-18 2024-11-07 Incyte Corporation 2-azabicyclo[2.2.1]heptane kras inhibitors

Family Cites Families (333)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3272781A (en) 1963-08-07 1966-09-13 American Potash & Chem Corp Boroureas of phosphinoborine polymers
FR1425700A (fr) 1965-02-22 1966-01-24 Basf Ag Composés formant des complexes métalliques et procédé pour les préparer et les utiliser
US4208328A (en) 1978-04-27 1980-06-17 General Electric Company Alkyl 3,5-dihydroxy-4-(2-benzothiazolyl)benzoates
US4789711A (en) 1986-12-02 1988-12-06 Ciba-Geigy Corporation Multifunctional epoxide resins
JPH0611031Y2 (ja) 1988-02-27 1994-03-23 タマパック株式会社 ゴルフ用パッティンググリーン
DE3828535A1 (de) 1988-08-23 1990-03-08 Basf Ag Benzimidazol-2-carbonsaeureanilide, ihre verwendung als lichtschutzmittel fuer organisches material und mit diesen aniliden stabilisiertes organisches material
US5077164A (en) 1989-06-21 1991-12-31 Minolta Camera Kabushiki Kaisha Photosensitive member containing an azo dye
EP0644460B1 (en) 1993-09-20 1999-12-08 Fuji Photo Film Co., Ltd. Positive working photoresist composition
JP3461397B2 (ja) 1995-01-11 2003-10-27 富士写真フイルム株式会社 ポジ型フオトレジスト組成物
WO1998027108A2 (en) 1996-12-16 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. New amide compounds and their use as nitric oxide synthase inhibitors
JPH10316853A (ja) 1997-05-15 1998-12-02 Sumitomo Bakelite Co Ltd 半導体多層配線用層間絶縁膜樹脂組成物及び該絶縁膜の製造方法
JP2001519345A (ja) 1997-10-02 2001-10-23 メルク エンド カムパニー インコーポレーテッド プレニルタンパク質トランスフェラーゼの阻害剤
AU2745899A (en) 1998-03-05 1999-09-20 Nissan Chemical Industries Ltd. Anilide compounds and herbicide
JP2000128984A (ja) 1998-10-28 2000-05-09 Sumitomo Bakelite Co Ltd ポリベンゾオキサゾール前駆体及び樹脂
JP2000128986A (ja) 1998-10-28 2000-05-09 Sumitomo Bakelite Co Ltd ポリベンゾオキサゾール前駆体及びポリベンゾオキサゾール
JP2000128987A (ja) 1998-10-28 2000-05-09 Sumitomo Bakelite Co Ltd ポリベンゾオキサゾール前駆体及びポリベンゾオキサゾール
US6297351B1 (en) 1998-12-17 2001-10-02 Sumitomo Bakelite Company Limited Polybenzoxazole resin and precursor thereof
CA2355249A1 (en) 1998-12-18 2000-06-22 Jason M. Hataye Protease inhibitors
JP2000212281A (ja) 1999-01-27 2000-08-02 Sumitomo Bakelite Co Ltd ポリベンゾオキサゾ―ル前駆体及びポリベンゾオキサゾ―ル樹脂
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
JP2001114893A (ja) 1999-10-15 2001-04-24 Sumitomo Bakelite Co Ltd ポリベンゾオキサゾール樹脂およびその前駆体
US6372907B1 (en) 1999-11-03 2002-04-16 Apptera Corporation Water-soluble rhodamine dye peptide conjugates
JP2001163975A (ja) 1999-12-03 2001-06-19 Sumitomo Bakelite Co Ltd ポリベンゾオキサゾール樹脂及びその前駆体
HUP0202263A3 (en) 1999-12-27 2003-02-28 Japan Tobacco Inc Benzimidazole, indole and imidazo-pyridine derivatives and pharmaceutical compositions containing them
ATE372337T1 (de) 2000-02-01 2007-09-15 Abbott Gmbh & Co Kg Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
EP1268478B1 (en) 2000-03-31 2007-05-02 Ortho-McNeil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
EP1278734A2 (en) 2000-04-24 2003-01-29 Merck Frosst Canada & Co. Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
PT1294358E (pt) 2000-06-28 2004-12-31 Smithkline Beecham Plc Processo de moagem por via humida
AU2001294515A1 (en) 2000-08-11 2002-02-25 The Regents Of The University Of California Use of stat-6 inhibitors as therapeutic agents
US20040058938A1 (en) 2000-12-13 2004-03-25 Oliver Cullmann Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
US6919352B2 (en) 2000-12-15 2005-07-19 Smithkline Beecham Corporation Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
SE0100567D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
AU2002258550B2 (en) 2001-03-14 2006-04-27 Eli Lilly And Company Retinoid X receptor modulators
EP1372643A1 (en) 2001-03-30 2004-01-02 Smithkline Beecham Corporation Pyrazolopyridines, process for their preparation and use as therapeutic compounds
US7141569B2 (en) 2001-04-10 2006-11-28 Smithkline Beecham Corporation Antiviral pyrazolopyridine compounds
JP2002316966A (ja) 2001-04-19 2002-10-31 Ueno Seiyaku Oyo Kenkyusho:Kk ビナフトール誘導体およびその製法
JP2004527560A (ja) 2001-04-27 2004-09-09 スミスクライン ビーチャム コーポレーション ピラゾロ［１，５−α］ピリジン誘導体
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
US20040214834A1 (en) 2001-09-07 2004-10-28 Kristjan Gudmunsson Pyrazolo-pyridines for the treatment of herpes infections
TWI320039B (en) 2001-09-21 2010-02-01 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
AU2002334969A1 (en) 2001-10-09 2003-04-22 Sylvie Barchechath Use of stat-6 inhibitors as therapeutic agents
BR0213208A (pt) 2001-10-09 2004-08-31 Upjohn Co Compostos de tetraidro- e hexaidro-carbazóis de arilsulfonila substituìda, suas composições e usos
JP4024579B2 (ja) 2002-01-22 2007-12-19 住友ベークライト株式会社 プラスチック光導波路用材料及び光導波路
NZ575692A (en) 2002-04-11 2009-10-30 Vertex Pharma Inhibitors of Serine Proteases, Particularly Hepatitis C Virus NS3-NS4 Protease
JP4500055B2 (ja) 2002-04-23 2010-07-14 塩野義製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン誘導体およびそれを含有するＮＡＤ（Ｐ）Ｈオキシダーゼ阻害剤
EP1541563A4 (en) 2002-07-10 2007-11-07 Ono Pharmaceutical Co ANTAGONIST OF CCR4 AND CORRESPONDING MEDICINAL USE
AU2003249244A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
JP2004059761A (ja) 2002-07-30 2004-02-26 Sumitomo Bakelite Co Ltd ポリベンゾオキサゾール樹脂、その前駆体及びこれらを用いた光導波路材料並びに光導波路
JP2004091369A (ja) 2002-08-30 2004-03-25 Sumitomo Pharmaceut Co Ltd 新規ビフェニル化合物
WO2004035522A1 (ja) 2002-08-30 2004-04-29 Bf Research Institute, Inc. プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤
JP2006504728A (ja) 2002-10-03 2006-02-09 スミスクライン ビーチャム コーポレーション ピラソロピリジン誘導体系治療用化合物
JP2006504755A (ja) 2002-10-15 2006-02-09 スミスクライン ビーチャム コーポレーション Ｇｓｋ−３阻害薬としてのピリダジン化合物
KR100624406B1 (ko) 2002-12-30 2006-09-18 삼성에스디아이 주식회사 비페닐 유도체 및 이를 채용한 유기 전계 발광 소자
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
JP4595288B2 (ja) 2003-03-25 2010-12-08 住友ベークライト株式会社 ポリベンゾオキサゾール樹脂、その前駆体及びこれらを用いた光導波路材料並びに光導波路
KR20060017494A (ko) 2003-04-11 2006-02-23 그렌마크 파머수티칼스 에스. 아. 염증 및 알레르기성 질환 치료용으로 유용한 신규 헤테로사이클릭 화합물, 이의 제조방법 및 이를 함유하는 약학 조성물
US7417065B2 (en) 2003-05-19 2008-08-26 Irm Llc Immunosuppressant compounds and compositions
JP2005002330A (ja) 2003-05-19 2005-01-06 Sumitomo Electric Ind Ltd 光学樹脂材料、光学素子、光モジュール、フッ素化ポリマー前駆体及びフッ素化ポリマー
US20060183746A1 (en) 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
CA2531856C (en) 2003-07-11 2013-07-30 Merck Patent Gesellschaft Mit Beschraenkter Haftung Benzimidazole carboxamides as raf kinase inhibitors
WO2005007628A1 (en) 2003-07-11 2005-01-27 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
EP1661879A4 (en) 2003-08-04 2006-11-29 Ono Pharmaceutical Co A DIPHENYL ETHER COMPOUND, PROCESS FOR THE PRODUCTION AND USE THEREOF
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
AU2004270733B2 (en) 2003-09-11 2011-05-19 Itherx Pharma, Inc. Cytokine inhibitors
CA2542105C (en) 2003-10-08 2011-08-02 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1679309A4 (en) 2003-10-24 2007-03-28 Ono Pharmaceutical Co ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
JP2007534652A (ja) 2003-12-23 2007-11-29 ビーエーエスエフ　アクチェンゲゼルシャフト ３−トリフルオロメチルピコリン酸アニリドおよび殺菌剤としてのその使用
CA2555402A1 (en) 2004-02-12 2005-09-01 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
JPWO2005077948A1 (ja) 2004-02-16 2008-01-10 第一製薬株式会社 抗真菌作用複素環化合物
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
JP2005248082A (ja) 2004-03-05 2005-09-15 Sumitomo Electric Ind Ltd ポリベンゾオキサゾール樹脂前駆体の製造方法およびポリベンゾオキサゾール樹脂の製造方法
CA2555914A1 (en) 2004-03-08 2005-09-22 Amgen Inc. Therapeutic modulation of ppar (gamma) activity
CA2554554A1 (en) 2004-03-08 2005-09-22 The University Of North Carolina At Chapel Hill Novel dicationic imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2a]pyridines as antiprotozoal agents
US7423147B2 (en) 2004-03-31 2008-09-09 Janssen Pharmaceutical, N.V. Pyridine compounds as histamine H3 modulators
JP2005290301A (ja) 2004-04-02 2005-10-20 Sumitomo Electric Ind Ltd ポリベンゾオキサゾール樹脂前駆体の製造方法およびポリベンゾオキサゾール樹脂の製造方法
WO2005099656A2 (en) 2004-04-06 2005-10-27 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
JP4879165B2 (ja) 2004-04-20 2012-02-22 トランス テック ファーマ，インコーポレイテッド メラノコルチン受容体の調節因子としての置換チアゾール及びピリミジン誘導体
DE102004021716A1 (de) 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
JP4865702B2 (ja) 2004-05-03 2012-02-01 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン阻害剤
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
BRPI0515596A (pt) 2004-09-23 2008-07-29 Wyeth Corp composição farmacêutica usada para o tratamento e/ou prevenção de hcv, e, métodos de inibir rna polimerase ns5b de hepatite c de tratar ou prevenir infecção por hepatite c em um mamìfero
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
BRPI0517619A (pt) 2004-11-10 2008-10-14 Cgi Pharmaceuticals Inc entidades quìmicas de imidazo[1,2-a] pirazin-8-ilaminas, suas composições farmacêuticas, uso dos referidos compostos na preparação de medicamento, processo de preparação de medicamento e métodos de utilização dos referidos compostos
DE102004054665A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
US7998974B2 (en) 2005-03-03 2011-08-16 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
EP1863766B1 (en) 2005-03-10 2015-05-20 Gilead Connecticut, Inc. Certain substituted amides, method of making, and method of use thereof
JP2006290883A (ja) 2005-03-17 2006-10-26 Nippon Nohyaku Co Ltd 置換ヘテロ環カルボン酸アニリド誘導体、その中間体及び農園芸用薬剤並びにその使用方法
US7566716B2 (en) 2005-05-20 2009-07-28 Array Biopharma Inc. Imidazopyrazines as Raf inhibitor compounds
US20080220968A1 (en) 2005-07-05 2008-09-11 Ge Healthcare Bio-Sciences Ab [1, 2, 4] Triazolo [1, 5-A] Pyrimidine Derivatives as Chromatographic Adsorbent for the Selective Adsorption of Igg
WO2007034282A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
ES2572263T3 (es) 2005-10-25 2016-05-31 Shionogi & Co Derivados de dihidrooxazina y tetrahidropirimidina como inhibidores de BACE 1
CA2630562C (en) 2005-11-22 2013-12-31 Merck & Co., Inc. Tricyclic compounds useful as inhibitors of kinases
WO2007067711A2 (en) 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
EP1961745A1 (en) 2005-12-12 2008-08-27 Ono Pharmaceutical Co., Ltd. Bicyclic heterocyclic compound
US20090281075A1 (en) 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
US20090304821A1 (en) 2006-03-08 2009-12-10 Takeda Pharmaceutical Company Limited Pharmaceutical Combination
MX2008012617A (es) 2006-03-31 2008-10-10 Novartis Ag Compuestos organicos.
EP2023919A4 (en) 2006-05-08 2010-12-22 Molecular Neuroimaging Llc COMPOUNDS AND AMYLOID PROBES FOR THERAPY AND IMAGING USES
WO2007146712A2 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
CA2658764A1 (en) 2006-07-20 2008-01-24 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
DE102006035018B4 (de) 2006-07-28 2009-07-23 Novaled Ag Oxazol-Triplett-Emitter für OLED-Anwendungen
WO2008021745A2 (en) 2006-08-16 2008-02-21 Itherx Pharmaceuticals, Inc. Hepatitis c virus entry inhibitors
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
US7563797B2 (en) 2006-08-28 2009-07-21 Forest Laboratories Holding Limited Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands
AR063706A1 (es) 2006-09-11 2009-02-11 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
US7838523B2 (en) 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
EP2074106B1 (en) 2006-09-11 2013-04-17 Mylan Laboratories Limited Dibenzofuran derivatives as inhibitors of pde-4 and pde-10
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
AR063707A1 (es) 2006-09-11 2009-02-11 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden.
FR2906250B1 (fr) 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
CA2667644A1 (en) 2006-10-27 2008-05-15 Wyeth Tricyclic compounds as matrix metalloproteinase inhibitors
AU2007317296B2 (en) 2006-11-08 2012-07-05 Bristol-Myers Squibb Company Pyridinone compounds
GB0623209D0 (en) 2006-11-21 2007-01-03 F2G Ltd Antifungal agents
WO2008064317A1 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
US20100004301A1 (en) 2006-12-14 2010-01-07 Benjamin Pelcman Benzoxazoles Useful in the Treatment of Inflammation
JP5492565B2 (ja) 2006-12-22 2014-05-14 インサイト・コーポレイション Ｊａｎｕｓキナーゼ阻害剤としての置換複素環
WO2008104077A1 (en) 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
EP1964841A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
EP1964840A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
JP2008218327A (ja) 2007-03-07 2008-09-18 Hitachi Ltd 電解質、電解質膜、それを用いた膜電極接合体、燃料電池電源及び燃料電池電源システム
JP2010120852A (ja) 2007-03-09 2010-06-03 Daiichi Sankyo Co Ltd 新規なジアミド誘導体
BRPI0809106A2 (pt) 2007-03-22 2014-08-26 Astrazeneca Ab Derivados de quinolina para o tratamento de doenças inflamatórias
MX2009011498A (es) 2007-04-24 2009-11-10 Shionogi & Co Derivados de aminodihidrotiazina sustituida con un grupo ciclico.
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
PT2155747E (pt) 2007-05-10 2012-12-19 Ge Healthcare Ltd Imidazol(1,2-a)piridinas e compostos relacionados com actividade nos receptores de canabinóides cb2
WO2009027733A1 (en) 2007-08-24 2009-03-05 Astrazeneca Ab (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
DE602008006209D1 (de) 2007-09-20 2011-05-26 Amgen Inc 1-(4-(4-benzylbenzamid)-benzyl)-azetidin-3-carboxylsäurederivate und entsprechende verbindungen als s1p-rezeptor-modulatoren zur behandlung von immunerkrankungen
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
TW200932219A (en) 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
WO2009053737A2 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
US7868001B2 (en) 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
CA2707491A1 (en) 2007-12-13 2009-06-18 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
RU2364597C1 (ru) 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
KR20100093569A (ko) 2007-12-19 2010-08-25 신젠타 파티서페이션즈 아게 살충성 화합물
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2231659A4 (en) 2007-12-21 2011-10-26 Univ Sydney LIGANDS OF THE TRANSLOCATION PROTEIN
BRPI0906962B8 (pt) 2008-01-18 2021-05-25 Eisai R&D Man Co Ltd composto de aminodiidrotiazina fundido
WO2009096202A1 (ja) 2008-01-31 2009-08-06 Konica Minolta Holdings, Inc. ハロ多環芳香族化合物及びその製造方法
EA201001359A1 (ru) 2008-02-26 2011-04-29 Новартис Аг Гетероциклические соединения в качестве ингибиторов cxcr2
EP2095818A1 (en) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
FR2928921B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique
FR2928924B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
FR2928922B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
JP5432982B2 (ja) 2008-03-31 2014-03-05 武田薬品工業株式会社 アポトーシスシグナル調節キナーゼ１阻害剤
KR101034351B1 (ko) 2008-05-14 2011-05-16 한국화학연구원 신규 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물
AU2009249186B2 (en) 2008-05-19 2014-05-22 Sunovion Pharmaceuticals Inc. Imidazo [1, 2-a] pyridine compounds as GABA-A receptor modulators
KR20110019385A (ko) 2008-05-29 2011-02-25 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 이미다조피리딘 및 관련 유사체
EP2323665B1 (en) 2008-07-24 2013-06-19 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
JP2011231017A (ja) 2008-09-09 2011-11-17 Nissan Chem Ind Ltd 光学活性エポキシ化合物及び光学活性スルホキシド化合物の製造方法、並びに該方法に用いる配位子、錯体及び該錯体の製造方法
WO2010056875A1 (en) 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
US20120010188A1 (en) 2008-12-04 2012-01-12 Promimagen Ltd. Imidazopyridine Compounds
BRPI0922565A2 (pt) 2008-12-19 2015-12-15 Bristol Myers Squibb Co compostos de carbazol carboxamida úteis como inibidores de cinase
US8815840B2 (en) 2008-12-19 2014-08-26 Bristol-Myers Squibb Company Carbazole and carboline kinase inhibitors
AR074830A1 (es) 2008-12-19 2011-02-16 Cephalon Inc Pirrolotriazinas como inhibidores de alk y jak2
JP5624275B2 (ja) 2008-12-22 2014-11-12 ユー・ディー・シー アイルランド リミテッド 有機電界発光素子
ES2567047T3 (es) 2008-12-23 2016-04-19 Abbvie Inc. Derivados de pirimidina anti-virales
JP5578490B2 (ja) 2008-12-26 2014-08-27 味の素株式会社 ピラゾロピリミジン化合物
JP2010202530A (ja) 2009-02-27 2010-09-16 Tokyo Institute Of Technology 含ヘテロ芳香族化合物および光学材料
WO2010104307A2 (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
EP2414328B1 (en) 2009-04-02 2021-05-26 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
US8778935B2 (en) 2009-04-16 2014-07-15 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyrazines for use as kinase inhibitors
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
JP2012532102A (ja) 2009-06-30 2012-12-13 シガ・テクノロジーズ・インコーポレーテッド デングウイルス感染の治療法および予防法
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
JP2011057661A (ja) 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US9095596B2 (en) 2009-10-15 2015-08-04 Southern Research Institute Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
JP6267863B2 (ja) 2009-10-16 2018-01-24 メリンタ セラピューティクス，インコーポレイテッド 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
JPWO2011078221A1 (ja) 2009-12-24 2013-05-09 味の素株式会社 イミダゾピリダジン化合物
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
WO2011097607A1 (en) 2010-02-08 2011-08-11 Southern Research Institute Anti-viral treatment and assay to screen for anti-viral agent
AR080433A1 (es) 2010-03-02 2012-04-11 Merck Sharp & Dohme Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen.
EP2542076B1 (en) 2010-03-04 2021-01-13 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
BR112012023576B1 (pt) 2010-03-18 2022-08-23 Institut Pasteur Korea Compostos anti-infecciosos e composições compreendendo os mesmos
US8410117B2 (en) 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
WO2011159857A1 (en) 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
CN102295642B (zh) 2010-06-25 2016-04-06 中国人民解放军军事医学科学院毒物药物研究所 2-芳基咪唑并[1,2-a]吡啶-3-乙酰胺衍生物、其制备方法及用途
EP2402345A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds
CN101891895B (zh) 2010-07-28 2011-11-30 南京航空航天大学 基于桥联双水杨醛结构的苯并噻唑类金属配位聚合物及其制法及应用
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
CN101993415B (zh) 2010-09-15 2013-08-14 北京韩美药品有限公司 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
US8921381B2 (en) 2010-10-04 2014-12-30 Baruch S. Blumberg Institute Inhibitors of secretion of hepatitis B virus antigens
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
US20140243324A1 (en) 2010-11-18 2014-08-28 Ligand Pharmaceuticals Incorporated Use of hematopoietic growth factor mimetics
US20130253011A1 (en) 2010-12-17 2013-09-26 Syngenta Participations Ag Insecticidal compounds
TWI617559B (zh) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
PE20140471A1 (es) 2011-01-04 2014-04-13 Novartis Ag Moduladores de la via del complemento y usos de los mismos
WO2012100342A1 (en) 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
US8921368B2 (en) 2011-03-17 2014-12-30 Bristol-Myers Squibb Company Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
MX2013011947A (es) 2011-04-13 2014-01-16 Merck Sharp & Dohme Iminotiazinas 5-sustituidas y sus monoxidos y dioxidos como inhibidores de la enzima que encinde la proteina precursora amiloide en el sitio beta, composiciones y su uso.
CN102796103A (zh) 2011-05-23 2012-11-28 南京英派药业有限公司 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用
EP2713722B1 (en) 2011-05-31 2017-03-15 Receptos, LLC Novel glp-1 receptor stabilizers and modulators
GB201109763D0 (en) 2011-06-10 2011-07-27 Ucl Business Plc Compounds
WO2012175991A1 (en) 2011-06-24 2012-12-27 Pharminox Limited Fused pentacyclic anti - proliferative compounds
EA201490229A1 (ru) 2011-07-08 2014-05-30 Новартис Аг Новые пирролопиримидиновые производные
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013040528A1 (en) 2011-09-16 2013-03-21 Microbiotix, Inc. Antimicrobial compounds
WO2013043521A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Pyrazolopyridyl compounds as aldosterone synthase inhibitors
JP6040677B2 (ja) 2011-09-29 2016-12-07 東洋インキＳｃホールディングス株式会社 太陽電池封止材用樹脂組成物
EA201490774A1 (ru) 2011-10-13 2014-08-29 Новартис Аг Новые производные оксазина и их применение при лечении заболевания
WO2013059594A1 (en) 2011-10-20 2013-04-25 Sirtris Pharmaceuticals, Inc. Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
KR20140090637A (ko) 2011-10-21 2014-07-17 토렌트 파마슈티칼스 리미티드 Ｇｐｂａｒ１ 수용체 조절인자들로서 신규 치환된 이미다조피리미딘들
WO2013120040A1 (en) 2012-02-10 2013-08-15 Children's Medical Center Corporation Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
JPWO2013133367A1 (ja) 2012-03-09 2015-07-30 カルナバイオサイエンス株式会社 新規トリアジン誘導体
KR20150002573A (ko) 2012-04-20 2015-01-07 길리애드 사이언시즈, 인코포레이티드 벤조티아졸-6-일 아세트산 유도체 및 ｈｉｖ 감염을 치료하기 위한 이의 용도
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
US20150105433A1 (en) 2012-04-27 2015-04-16 The Uab Research Foundation TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM
EP2862853B1 (en) 2012-06-18 2020-01-22 Sumitomo Chemical Co., Ltd Fused heterocyclic compound
EP2871179A4 (en) 2012-07-03 2016-03-16 Ono Pharmaceutical Co CONNECTION WITH AGONISTIC EFFECT ON THE SOMATOSTATIN RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
WO2014009295A1 (en) 2012-07-13 2014-01-16 Ucb Pharma S.A. Imidazopyridine derivatives as modulators of tnf activity
JP2015178457A (ja) 2012-07-25 2015-10-08 杏林製薬株式会社 ピラゾロピリジン誘導体、またはその薬理学的に許容される塩
WO2014039595A1 (en) 2012-09-06 2014-03-13 Bristol-Myers Squibb Company Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
RS60202B1 (sr) 2012-09-26 2020-06-30 Hoffmann La Roche Jedinjenja cikličnog etra pirazol-4-il-heterociklil-karboksamida i postupci primene
WO2014061693A1 (ja) 2012-10-17 2014-04-24 塩野義製薬株式会社 新規非芳香族炭素環又は非芳香族複素環誘導体
WO2014081878A2 (en) 2012-11-21 2014-05-30 Stategics, Inc. Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival
JP6037804B2 (ja) 2012-12-03 2016-12-07 富士フイルム株式会社 ガス分離膜
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
US20150376172A1 (en) 2013-01-22 2015-12-31 Thomas Woltering Fluoro-[1,3]oxazines as bace1 inhibitors
CN103933036B (zh) 2013-01-23 2017-10-13 中国人民解放军军事医学科学院毒物药物研究所 2‑芳基咪唑并[1,2‑α]吡啶‑3‑乙酰胺衍生物在制备防治PTSD的药物中的用途
EP2950814A4 (en) 2013-01-31 2016-06-08 Univ Jefferson PD-L1 AND PD-L2 BASED FUSION PROTEINS AND USES THEREOF
CA2902781C (en) 2013-02-27 2020-12-29 Mochida Pharmaceutical Co., Ltd. Novel pyrazole derivative
BR112015021336A2 (pt) 2013-03-08 2017-07-18 Amgen Inc compostos 1,3-oxazin-2-amina fundidos ciclopropil perfluorados como inibidores de beta-secretase e métodos de uso
CN104045552B (zh) 2013-03-13 2019-06-11 江苏先声药业有限公司 作为神经保护剂的药用化合物
CN105283552A (zh) 2013-03-13 2016-01-27 澳大利亚核科学和技术组织 具有非功能性tspo基因的转基因非人类生物体
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
HUE039473T2 (hu) 2013-03-14 2019-01-28 Curadev Pharma Private Ltd Kinurenin útvonal inhibitorok
BR112015022227A2 (pt) 2013-03-14 2017-07-18 Celtaxsys Inc inibidores de leucotrieno a4 hidrolase
CN105189503B (zh) 2013-03-14 2017-03-22 百时美施贵宝公司 人免疫缺陷病毒复制的抑制剂
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
NZ754039A (en) 2013-06-26 2021-06-25 Abbvie Inc Primary carboxamides as btk inhibitors
WO2015000715A1 (en) 2013-07-02 2015-01-08 Syngenta Participations Ag Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents
EP3022199A1 (en) 2013-07-17 2016-05-25 Otsuka Pharmaceutical Co., Ltd. Cyanotriazole compounds
US9975896B2 (en) 2013-07-25 2018-05-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
EP2835375A1 (en) 2013-08-09 2015-02-11 Fundació Institut Català d'Investigació Química Bis-salphen compounds and carbonaceous material composites comprising them
KR101715090B1 (ko) 2013-08-28 2017-03-13 한국화학연구원 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물
AU2014315457B2 (en) 2013-09-04 2018-05-10 Bristol-Myers Squibb Company Compounds useful as immunomodulators
CU24345B1 (es) 2013-09-06 2018-05-08 Aurigene Discovery Tech Ltd Derivados de 1,3,4-oxadiazol y 1,3,4-tiadiazol como inmunomoduladores
PL3363790T3 (pl) 2013-09-06 2020-07-27 Aurigene Discovery Technologies Limited Pochodne 1,2,4-oksadiazolu jako immunomodulatory
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
JP6336870B2 (ja) 2013-09-30 2018-06-06 日本ポリプロ株式会社 ビフェノール化合物及びそれを用いるオレフィン重合用触媒並びにオレフィン重合体の製造方法
FR3012140B1 (fr) 2013-10-18 2016-08-26 Arkema France Unite et procede pour la purification de methacrylate de methyle brut
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321736D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321733D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015095337A2 (en) 2013-12-18 2015-06-25 The Rockefeller University PYRAZOLO[1,5-a]PYRIMIDINECARBOXAMIDE DERIVATIVES FOR TREATING COGNITIVE IMPAIRMENT
RU2016131792A (ru) 2014-01-03 2018-02-06 Байер Энимэл Хельс ГмбХ Новые пиразолил-гетероариламиды в качестве средств для борьбы с вредителями
AU2015213735A1 (en) 2014-02-10 2016-08-04 Merck Sharp & Dohme Corp. Antibodies that bind to human Tau and assay for quantifying human Tau using the antibodies
MX2016011038A (es) 2014-02-25 2017-05-12 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos mediados por complemento.
JP6490464B2 (ja) 2014-03-26 2019-03-27 三井化学株式会社 遷移金属化合物、オレフィン重合用触媒およびオレフィン系重合体の製造方法
MX2016012984A (es) 2014-04-04 2017-05-09 Iomet Pharma Ltd Derivados indol para uso en medicina.
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
CN106065009B (zh) 2014-06-28 2019-03-01 广东东阳光药业有限公司 作为丙型肝炎抑制剂的化合物及其在药物中的应用
CN104211726B (zh) 2014-08-11 2017-06-16 中南民族大学 非茂类三齿双核钛配合物、制备方法及用途
JP2017530959A (ja) 2014-09-17 2017-10-19 エピザイム，インコーポレイティド Ｃａｒｍ１阻害剤およびその使用
WO2016041511A1 (en) 2014-09-19 2016-03-24 Yen-Ta Lu Benzo-heterocyclic compounds and their applications
AU2015328285B2 (en) 2014-10-06 2019-07-18 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
CA2968884A1 (en) 2014-12-10 2016-06-16 Massachusetts Institute Of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
JP6853619B2 (ja) 2015-01-16 2021-03-31 大塚製薬株式会社 シアノトリアゾール化合物の医薬用途
WO2016116525A1 (de) 2015-01-20 2016-07-28 Cynora Gmbh Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen
US10071998B2 (en) 2015-01-20 2018-09-11 Merck Sharp & Dohme Corp. Iminothiadiazine dioxides bearing an amine-linked substituent as BACE inhibitors, compositions, and their use
WO2016156282A1 (en) 2015-04-02 2016-10-06 Bayer Cropscience Aktiengesellschaft Novel triazole compounds for controlling phytopathogenic harmful fungi
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
WO2017070320A1 (en) 2015-10-21 2017-04-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Phenyl indole allosteric inhibitors of p97 atpase
KR101717601B1 (ko) 2015-11-10 2017-03-20 한국화학연구원 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물
MX2018006207A (es) 2015-11-19 2018-09-05 Incyte Corp Compuestos heterociclicos como inmunomoduladores.
WO2017106634A1 (en) 2015-12-17 2017-06-22 Incyte Corporation N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
JP6943857B2 (ja) 2015-12-22 2021-10-06 シンジェンタ パーティシペーションズ アーゲー 有害生物防除活性ピラゾール誘導体
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
AU2016378482A1 (en) 2015-12-22 2018-07-12 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
TWI850624B (zh) 2015-12-22 2024-08-01 美商英塞特公司 作為免疫調節劑之雜環化合物
KR101653560B1 (ko) 2016-02-02 2016-09-12 한국화학연구원 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물
US20170320875A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
MX2018016295A (es) 2016-06-20 2019-09-16 Elanco Us Inc Interferon porcino pegilado y metodos de utilizacion del mismo.
IL263429B (en) 2016-06-20 2022-08-01 Novartis Ag Crystalline forms of a triazolopyrimidine compound
MD3472167T2 (ro) 2016-06-20 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018026971A1 (en) * 2016-08-03 2018-02-08 Arising International, Llc Symmetric or semi-symmetric compounds useful as immunomodulators
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
SG10202101986UA (en) 2016-08-30 2021-04-29 Tetraphase Pharmaceuticals Inc Tetracycline compounds and methods of treatment
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
US10858364B2 (en) 2016-12-21 2020-12-08 Acerta Pharma B.V. Imidazopyrazine inhibitors of Bruton's tyrosine kinase
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
DK3559009T3 (da) 2016-12-22 2021-05-03 Calithera Biosciences Inc Sammensætninger og metoder til inhibition af arginaseaktivitet
CA3047991A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
MY197501A (en) * 2016-12-22 2023-06-19 Incyte Corp Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CA3070794A1 (en) 2017-07-28 2019-01-31 Chemocentryx, Inc. Immunomodulator compounds
ES2926540T3 (es) 2017-08-08 2022-10-26 Chemocentryx Inc Inmunomoduladores macrocíclicos
CN109400522B (zh) 2017-08-18 2023-04-28 上海轶诺药业有限公司 一种具有pd-l1抑制活性的化合物、其制备方法及用途
WO2019191707A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2019192506A1 (en) 2018-04-03 2019-10-10 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
FI3790877T3 (fi) 2018-05-11 2023-05-09 Incyte Corp Tetrahydroimidatso[4,5-c]pyridiinijohdannaisia pd-l1-immunomodulaattoreina
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020088357A1 (zh) 2018-11-02 2020-05-07 上海再极医药科技有限公司 联苯类化合物、其中间体、制备方法、药物组合物及应用
SG11202108367XA (en) 2019-01-31 2021-08-30 Betta Pharmaceuticals Co Ltd Immunomodulators, compositions and methods thereof
MX2022001671A (es) 2019-08-09 2022-05-13 Incyte Corp Sales de un inhibidor de pd-1/pd-l1.
CA3155852A1 (en) 2019-09-30 2021-04-08 Incyte Corporation PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AS IMMUNOMODULATORS
AU2020385113A1 (en) 2019-11-11 2022-05-19 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor

Also Published As

Publication number Publication date
US20190345170A1 (en) 2019-11-14
MD3790877T2 (ro) 2023-08-31
TW201946626A (zh) 2019-12-16
CR20200614A (es) 2021-04-27
JOP20200288A1 (ar) 2020-11-11
ECSP20079887A (es) 2021-03-31
AU2019267824A1 (en) 2021-01-07
WO2019217821A1 (en) 2019-11-14
CN112752756A (zh) 2021-05-04
US10906920B2 (en) 2021-02-02
US20210115068A1 (en) 2021-04-22
CL2020002922A1 (es) 2021-04-16
PH12020551927A1 (en) 2021-06-14
FI3790877T3 (fi) 2023-05-09
EP4219492A1 (en) 2023-08-02
LT3790877T (lt) 2023-05-10
MX2020012045A (es) 2021-03-29
US20200277309A1 (en) 2020-09-03
CN118908978A (zh) 2024-11-08
BR112020022936A2 (pt) 2021-02-02
US20220348594A1 (en) 2022-11-03
DK3790877T3 (da) 2023-04-24
US11414433B2 (en) 2022-08-16
TW202425987A (zh) 2024-07-01
PE20211918A1 (es) 2021-09-28
MX2023013685A (es) 2024-01-08
CO2020015437A2 (es) 2021-01-18
PT3790877T (pt) 2023-05-10
HUE061503T2 (hu) 2023-07-28
US10618916B2 (en) 2020-04-14
AU2023227554A1 (en) 2023-09-28
JP7328995B2 (ja) 2023-08-17
RS64188B1 (sr) 2023-06-30
ES2943028T3 (es) 2023-06-08
CL2021002995A1 (es) 2022-06-24
AU2019267824B2 (en) 2023-10-05
SA520420524B1 (ar) 2024-02-15
EP3790877B1 (en) 2023-03-01
EP3790877A1 (en) 2021-03-17
PL3790877T3 (pl) 2023-06-12
SI3790877T1 (sl) 2023-06-30
JP2023162216A (ja) 2023-11-08
CA3099994A1 (en) 2019-11-04
TWI821288B (zh) 2023-11-11
JP2021524842A (ja) 2021-09-16
KR20210018282A (ko) 2021-02-17
CN112752756B (zh) 2024-06-25
SG11202011165TA (en) 2020-12-30

Similar Documents

Publication Publication Date Title
HRP20230306T1 (hr) Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori
HRP20221216T1 (hr) Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1
HRP20230377T1 (hr) Inhibitori mutacije kras g12c
AU2018200876B2 (en) Inhibitors of histone demethylases
CN107304191B (zh) 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
CA2472372C (en) Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
HRP20170802T1 (hr) Supstituirani triciklički benzimidazoli kao inhibitori kinaze
JPWO2021067217A5 (hr)
ES2432070T3 (es) Diazaheteroarilos broncodilatadores novedosos
ES2614034T3 (es) Derivados de amidina tricíclica como inhibidores de la unión del VIH
WO2013013504A1 (zh) 替加环素衍生物
RU2011101898A (ru) Триазолпиридиновые соединения, ингибирующие jak, и способы
CN102548994A (zh) 用于制备用作蛋白激酶抑制剂的嘧啶衍生物的方法
EP3414251A1 (en) Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors
RU2656209C2 (ru) Терапевтически активные производные оксазолина
WO2016095089A1 (en) Erk inhibitors
ES2819249T3 (es) Derivados de tetrahidroimidazopiridina como moduladores de la actividad de TNF
CA3019026A1 (en) Fused pentacyclic imidazole derivatives as modulators of tnf activity
RU2019112863A (ru) Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
US11358967B2 (en) Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma
WO2017181849A1 (zh) 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
ES2914526T3 (es) Composiciones de biarilo y métodos para modular una cascada de cinasa
US8685982B2 (en) Thioamide, amidoxime and amidrazone derivatives as HIV attachment inhibitors
AU2023224879A1 (en) Protacs of malt1
CA3160195A1 (en) Prmt5 inhibitors